cancer – media

CRUK researchers develop new early-stage rectal cancer treatment

Cancer Research UK (CRUK) researchers have developed a new treatment for early-stage rectal cancer which they say could provide patients with an improved quality of life. In a pilot study of the new treatment option, which combines local keyhole surgery and radiotherapy, researchers found that they could prevent debilitating side effects such as diarrhoea and the need for a permanent colostomy bag. This study, dubbed TREC, enrolled 123 patients with early-stage rectal cancer, with 61 patients receiving the newly-developed treatment approach. In addition, 55 patients were randomised to two treatment approaches – 28 received major surgery and 27 received the new organ preserving treatment. Within the patient population who received the new treatment, 70% were treated successfully, meaning their tumour was removed while preserving the rest of their rectum and the cancer did not return during the three to five-year follow-up period. Patients who received the new treatment also reported ...
- Source: drugdu
- 569
- December 12, 2020
cancer
Study Discovers New Mechanism of Immune System to Fight Disease

The disease-fighting capacity of the body depends on the proper functioning of its immune system. Hence, a new discovery revealing new insight into its functioning by University of Queensland (UQ) researchers could reveal new ways to treat diseases like cancer and autoimmune disorders.
- Source: MedicalXpress
- 2,013
- September 3, 2018
cancer immune system Researches
J&J Prepares for Appeal after Judge’s Multibillion-Dollar Verdict Against its Talc Defence

The jury at the St. Louis court announced its verdict against J&J last month, giving a major blow to the company as it now has to pay about $4.7 billion to 22 women or their loved-ones for the claim that it’s talc caused ovarian cancer.
- Source: FiercePharma
- 888
- August 27, 2018
cancer Company Insight Johnson & Johnson lawsuit
Bristol-Myers to sell Opdivo in China at Half its Cost in the U.S.A

The much-awaited tagging of the price of Bristol-Myers Squibb’s PD-1 hero Opdivo in China was finally revealed by the company to be half of its cost in the U.S.
- Source: FiercePharma
- 952
- August 24, 2018
cancer Company Insight Opdivo
Bristol-Myers Squibb’s Opdivo Ensures a Lung Cancer Position

Bristol-Myers Squibb secured a standing in the small cell lung cancer domain making up for its slower growth in the non-small cell lung cancer market compared to its counterpart, Merck.
- Source: FiercePharma
- 1,209
- August 22, 2018
BMS cancer FDA New Approvals
Study Links Smoking, Drinking to SLE risk in Black Women

Cigarette smoking in black women leads to higher incidences of systemic lupus erythematosus (SLE) whereas moderate consumption of alcohol showed a lower risk, revealed data from the prospective Black Women’s Health Study.
- Source: MDEdge
- 977
- August 21, 2018
cancer Researches systemic lupus erythematosus
Artios Pharma raises $84 Million to take DDR Programs to Next Level

Artios Pharma, a U.K. based company in Cambridge, has raised $84 million to take DNA damage response (DDR) programs to the next level of clinical proof of concept.
- Source: FierceBiotech
- 1,057
- August 14, 2018
cancer Company Insight DNA
New Blood Test Foresees Risk for Kidney Cancer and Survival Five Years before Diagnosis

The most prevalent type of kidney cancer, clear cell kidney cancer, could be predicted years prior to clinical diagnosis by a crucial biomarker of kidney disease.
- Source: EurekAlert
- 898
- August 14, 2018
blood test cancer kidney cancer Researches
U.S. Insurers Baffled on Revelation of $4.7 billion J&J Talc Judgement

Wall Street is unclear whether the U.S. insurance industry will have to pay any costs from the $4.69 billion verdict against Johnson & Johnson granted to customers and their families who alleged that asbestos-adulterated talc leads to ovarian cancer.
- Source: Reuters
- 869
- August 3, 2018
cancer Company Insight Johnson & Johnson lawsuit
Silencing Protein could Enhance Immunotherapy Efficacy in Cancer Tumors

Silencing an earlier known protein could hamper tumor development and increase the efficacy of immunotherapy treatments, researchers discovered at the Bloomberg~Kimmel Institute for Cancer Immunotherapy in the Johns Hopkins Kimmel Cancer Center.
- Source: MedicalXpress
- 744
- August 2, 2018
cancer immunotherapies Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.